Form 8-K - Current report:
SEC Accession No. 0001193125-22-015445
Filing Date
2022-01-24
Accepted
2022-01-24 07:16:10
Documents
14
Period of Report
2022-01-24
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d266758d8k.htm   iXBRL 8-K 25558
2 EX-99.1 d266758dex991.htm EX-99.1 16216
6 GRAPHIC g266758dsp1.jpg GRAPHIC 22028
  Complete submission text file 0001193125-22-015445.txt   200010

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA hcwb-20220124.xsd EX-101.SCH 2861
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE hcwb-20220124_lab.xml EX-101.LAB 17980
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE hcwb-20220124_pre.xml EX-101.PRE 11262
8 EXTRACTED XBRL INSTANCE DOCUMENT d266758d8k_htm.xml XML 3315
Mailing Address 2929 N COMMERCE PKWY MIRAMAR FL 33025
Business Address 2929 N COMMERCE PKWY MIRAMAR FL 33025 954-842-2024
HCW Biologics Inc. (Filer) CIK: 0001828673 (see all company filings)

EIN.: 825024477 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40591 | Film No.: 22547544
SIC: 2834 Pharmaceutical Preparations